Castro C, Mordin M, Islam Z, Tu N, Hackshaw MD, Salas M. A review of non-disease specific health-related quality of life measures with reliability and validity evidence in patients with breast cancer. Poster presented at the 2020 ISPOR Virtual Conference; May 2020. [abstract] Value Health. 2020 May 1; 23(Suppl 1):S81.

OBJECTIVES: While disease-specific patient reported outcome measures (PROMs) are preferable, appropriately validated generic PROMs can also gather important insights not otherwise captured in disease-specific PROMs. Our aim is to identify and describe the health-related quality of life (HRQoL) PROMs which have evidence of reliability and validity among women with breast cancer for potential use in patients treated for breast cancer.

METHODS: A systematic literature review was conducted using PubMed, Embase, and PsycINFO databases from 01/09-08/19 to identify articles that contain psychometric properties (e.g. reliability, validity) of HRQoL PROMs used in patients with breast cancer (excluding surgery). English-language publications that reported psychometric properties of HRQoL PROMs were included.

RESULTS: A total of 613 unique records were identified. Of the 130 full-text articles reviewed, 80 presented psychometric data for PROMs used in breast cancer, including survivors. A total of 34 papers presented breast-cancer-specific PROMs (e.g. EORTC QLQ-BR23) and are reported elsewhere. This abstract focuses on the 22 papers that described psychometric properties of 20 non-breast cancer-specific HRQoL PROMs. Six of the PROMs were generic HRQoL measures (e.g. SF-12, EQ-5D, WHOQOL). The majority of the PROMs (14/20) were cancer-specific and focused on general HRQoL (e.g. Cancer Behavior Inventory), symptom inventories (e.g. PRO-CTCAE), or measured individual symptoms, concepts, or treatment-related toxicities (e.g. alopecia, anxiety, cognitive function). All identified generic measures demonstrated adequate reliability (e.g. test-retest, internal consistency), except for the SF-12; all demonstrated acceptable validity. Similarly, adequate reliability data was identified in 11/14 cancer-specific PROMs. Only 2 of 14 cancer-specific PROMs did not have specific validity data.

CONCLUSIONS: Evidence of both reliability and validity is necessary when choosing a PROM. Most, but not all, of the identified non-breast-cancer-specific HRQoL PROMs have evidence of reliability and validity among patients with breast cancer. These PROMs can help provide additional insight to patients experience with treatment.

Share on: